Coda Biotherapeutics

CODA Biotherapeutics is developing a novel chemogenetic platform for modulating the activity of neurons. In the CODA approach, viral vectors directly administered to target neurons deliver engineered neurotransmitter receptors that respond exclusively to non-native safe, orally bio-available drugs. Drug is then administered to activate or silence the targeted neurons, depending on the receptor that was delivered. The approach will be used to treat neuropathic pain, epilepsy, movement disorders and other severe nervous system disorders.
Commencement date
06/15/2017